305 related articles for article (PubMed ID: 12485451)
1. A novel immunosuppressive 1alpha,25-dihydroxyvitamin D3 analog with reduced hypercalcemic activity.
Zügel U; Steinmeyer A; Giesen C; Asadullah K
J Invest Dermatol; 2002 Dec; 119(6):1434-42. PubMed ID: 12485451
[TBL] [Abstract][Full Text] [Related]
2. 1α,25-Dihydroxyvitamin D3 and its analogs as modulators of human dendritic cells: a comparison dose-titration study.
Ferreira GB; Overbergh L; Verstuyf A; Mathieu C
J Steroid Biochem Mol Biol; 2013 Jul; 136():160-5. PubMed ID: 23098690
[TBL] [Abstract][Full Text] [Related]
3. Signaling of monocytic differentiation by a non-hypercalcemic analog of vitamin D3, 1,25(OH)2-5,6 trans-16-ene-vitamin D3, involves nuclear vitamin D receptor (nVDR) and non-nVDR-mediated pathways.
Ji Y; Wang X; Donnelly RJ; Uskokovic MR; Studzinski GP
J Cell Physiol; 2002 May; 191(2):198-207. PubMed ID: 12064463
[TBL] [Abstract][Full Text] [Related]
4. New 19-nor-(20S)-1alpha,25-dihydroxyvitamin D3 analogs strongly stimulate osteoclast formation both in vivo and in vitro.
Sato M; Nakamichi Y; Nakamura M; Sato N; Ninomiya T; Muto A; Nakamura H; Ozawa H; Iwasaki Y; Kobayashi E; Shimizu M; DeLuca HF; Takahashi N; Udagawa N
Bone; 2007 Feb; 40(2):293-304. PubMed ID: 17070129
[TBL] [Abstract][Full Text] [Related]
5. A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia.
Abe J; Nakano T; Nishii Y; Matsumoto T; Ogata E; Ikeda K
Endocrinology; 1991 Aug; 129(2):832-7. PubMed ID: 1855478
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulation by a novel, dissociated Vitamin D analogue.
Zügel U; Steinmeyer A; May E; Lehmann M; Asadullah K
Exp Dermatol; 2009 Jul; 18(7):619-27. PubMed ID: 19239489
[TBL] [Abstract][Full Text] [Related]
7. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
Kubota T; Koshizuka K; Koike M; Uskokovic M; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3370-5. PubMed ID: 9699668
[TBL] [Abstract][Full Text] [Related]
8. Biologic activity of dihydroxylated 19-nor-(pre)vitamin D3.
Bouillon R; Sarandeses LA; Allewaert K; Zhao J; Mascareñas JL; Mouriño A; Vrielynck S; de Clercq P; Vandewalle M
J Bone Miner Res; 1993 Aug; 8(8):1009-15. PubMed ID: 8213251
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibition of HT-29 human colon cancer cells by analogues of 1,25-dihydroxyvitamin D3.
Shabahang M; Buras RR; Davoodi F; Schumaker LM; Nauta RJ; Uskokovic MR; Brenner RV; Evans SR
Cancer Res; 1994 Aug; 54(15):4057-64. PubMed ID: 8033137
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D analogs, 20-Epi-22-oxa-24a,26a,27a,-trihomo-1alpha,25(OH)2-vitamin D3, 1,24(OH)2-22-ene-24-cyclopropyl-vitamin D3 and 1alpha,25(OH)2-lumisterol3 prime NB4 leukemia cells for monocytic differentiation via nongenomic signaling pathways, involving calcium and calpain.
Berry DM; Meckling-Gill KA
Endocrinology; 1999 Oct; 140(10):4779-88. PubMed ID: 10499538
[TBL] [Abstract][Full Text] [Related]
11. 24- and 26-homo-1,25-dihydroxyvitamin D3: preferential activity in inducing differentiation of human leukemia cells HL-60 in vitro.
Ostrem VK; Tanaka Y; Prahl J; DeLuca HF; Ikekawa N
Proc Natl Acad Sci U S A; 1987 May; 84(9):2610-4. PubMed ID: 3033654
[TBL] [Abstract][Full Text] [Related]
12. Development of the cell contact-mediated accessory function for T-cell proliferation in a human promyelocytic leukaemia cell line, HL-60, by 1,25-dihydroxyvitamin D3.
Shinbori T; Yamada M; Kakimoto K; Araki S; Onoue K
Immunology; 1992 Apr; 75(4):619-25. PubMed ID: 1350568
[TBL] [Abstract][Full Text] [Related]
13. The effects of 1alpha,24(S)-dihydroxyvitamin D(2) analog on cancer cell proliferation and cytokine expression.
Shany S; Levy Y; Lahav-Cohen M
Steroids; 2001; 66(3-5):319-25. PubMed ID: 11179740
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy.
Díaz GD; Paraskeva C; Thomas MG; Binderup L; Hague A
Cancer Res; 2000 Apr; 60(8):2304-12. PubMed ID: 10786699
[TBL] [Abstract][Full Text] [Related]
15. Methyl-introduced A-ring analogues of 1alpha,25-dihydroxyvitamin D3: synthesis and biological evaluation.
Fujishima T; Tsutsumi R; Negishi Y; Fujii S; Takayama H; Kittaka A; Kurihara M
Anticancer Res; 2006; 26(4A):2633-6. PubMed ID: 16886673
[TBL] [Abstract][Full Text] [Related]
16. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
17. Recent developments of 19-nor-1,25-dihydroxyvitamin D3 analogues.
Zhang CF; Wan RZ; Liu ZP
ChemMedChem; 2013 Aug; 8(8):1249-60. PubMed ID: 23788554
[TBL] [Abstract][Full Text] [Related]
18. An analog of 1alpha,25-dihydroxy-19-norvitamin D3 with the 1alpha-hydroxy group fixed in the axial position lacks biological activity in vitro.
Sicinski RR; Glebocka A; Plum LA; DeLuca HF
J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):293-7. PubMed ID: 17223547
[TBL] [Abstract][Full Text] [Related]
19. Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells.
Sochorová K; Budinský V; Rozková D; Tobiasová Z; Dusilová-Sulková S; Spísek R; Bartůnková J
Clin Immunol; 2009 Oct; 133(1):69-77. PubMed ID: 19660988
[TBL] [Abstract][Full Text] [Related]
20. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs.
Griffin MD; Lutz WH; Phan VA; Bachman LA; McKean DJ; Kumar R
Biochem Biophys Res Commun; 2000 Apr; 270(3):701-8. PubMed ID: 10772887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
